Overview

Corporate Presentation

Corporate Presentation - October 2024

Download Presentation

Email Alerts

Register to receive real time alerts

Sign Up

IR Contacts

Get in touch with our IR team

Contact Us

Latest Press Releases
Oct 3, 2024

Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP)...

Sep 30, 2024

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in...

Sep 26, 2024

Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER NEW HAVEN, Conn., Sept. 26, 2024 /PRNewswire/ --...

View All Press Releases

Events
Thursday, September 19, 2024
8:35am - 9:05am CDT

Corporate Presentation: September 19, 8:35 a.m. – 9:05 a.m. CET, Track 6

View All Events

We are developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis. Haduvio has a unique mechanism of action that targets cough centrally and peripherally and has the potential for a synergistic anti-tussive effect to treat chronic cough.

Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of chronic cough patients who currently have few treatment options.

Explore Our Pipeline